Review Maps the Case for Enhanced Point-of-Care Diagnostics in Deep Space Missions
This review evaluates current clinical laboratory capabilities aboard the ISS and argues that missions beyond low Earth orbit will require substantially expanded POCT biomarker panels. The authors highlight the need for high-sensitivity cardiac troponin at the point of care and propose using reference change values derived from longitudinal in-flight monitoring rather than terrestrial cut-offs to interpret results in microgravity.
The original study
Point of care testing of biochemical markers for monitoring astronauts during long duration missions in deep space.
- Authors
- Ferraro S, Sengupta S, Shaw J, Dave A, Cheli M, Colon R, et al.
- Journal
- Clinical chemistry and laboratory medicine
- Type
- Journal Article, Review
- PMID
- 41140086
Original abstract
BACKGROUND: Investigations into human performance and health status during long-duration spaceflights are ongoing aboard the International Space Station (ISS) and are critical for planning missions beyond Low Earth Orbit (LEO). This review evaluates the current evidence on point-of-care-testing (POCT) in space, discussing requirements for POCT to support astronaut health during extended deep space missions and the potential for technology transfer to terrestrial healthcare. CONTENTS: Microgravity disrupts biochemical and hormonal regulation, leading to reversible homeostatic dysregulation across multiple organ systems in astronauts during spaceflight in LEO. Missions beyond LEO may significantly increase risks of morbidity and mortality in particular for cardiovascular disease. The ability to assess key organ functions by expanding the range of detectable biomarkers on POCTs is crucial for ongoing health monitoring, urgent clinical decisions, and future mission planning. The recent implementation of high-sensitivity cardiac troponin I on POCT will be essential for early identifying myocardial injury and facilitating telemedicine support. Furthermore, the development and use of reference change values (RCV) in space environment, derived from biomarkers measured longitudinally in real-time onboard, will be crucial to differentiate clinically relevant changes in biomarkers levels from alterations induced by microgravity. This approach may overcome the use of traditional cut-off values which are assessed and generally applied under stable terrestrial conditions. SUMMARY: Clinical laboratory capabilities on the ISS are currently minimal. As missions lengthen, and extend beyond LEO, enhanced POCT is needed. Limited data on POCT performance in space highlight the importance of laboratory professionals' involvement to ensure high-quality testing and accurate interpretation.